Curated news and analysis on clinical trials, drug approvals, and medical research.
Calidi Biotherapeutics presented preclinical data on its RedTail virotherapy platform at the 2026 AACR Immuno-Oncology conference, demonstrating tumor-localized BiTE expression and IL-15 superagonist delivery. The company plans to submit an IND application for CLD-401 by end of 2026.
Merck KGaA has entered a partnership with Calla Lily Clinical Care to advance Callavid, an intravaginal drug delivery platform designed to address patient challenges in women's health therapeutics, with initial focus on fertility and pregnancy applications.
Ligand Pharmaceuticals will release Q4 and full year 2025 financial results on February 26, 2026, following recent share price declines despite strong annual returns. The company reported annual revenue of $251.233 million and net income of $48.581 million.
Initiative Foods recalls Tippy Toes fruit puree over elevated mold toxin levels, while new research reveals 71% of U.S. baby food products are ultra-processed with high sugar and additives.
PTC Therapeutics has withdrawn its New Drug Application resubmission for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy following FDA feedback that the data are unlikely to meet the threshold for substantial evidence of effectiveness.
The European Commission has granted marketing authorization for Moderna's mNEXSPIKE (mRNA-1283) COVID-19 vaccine for individuals aged 12 years and older across all 27 EU member states plus Iceland, Liechtenstein and Norway.
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
President Trump signed a spending package funding the National Institutes of Health at nearly $49 billion, the highest level ever, reversing his earlier push for a 40% budget cut to medical research.
The FDA announced a full reassessment of butylated hydroxyanisole (BHA), a chemical preservative used in packaged foods, to determine if it remains safe based on current science. The review follows decades of concerns about BHA being listed as "reasonably anticipated to be a human carcinogen."
A trial at Tygerberg Hospital in Cape Town tested DM199, a drug originally developed for stroke, in pregnant women with severe preeclampsia. The drug stabilized dangerously high blood pressure after researchers found the effective dose in the 16th patient.
Obesity contributes to about 1 in every 4 infectious disease deaths in the United States and 1 in 10 globally, according to a major study. People with obesity face 70% higher risk of hospitalization or death from infections, with risk tripling at severe obesity levels.
Measles cases are rising across multiple states, with over 40 cases at a Florida college and 18 cases in North Carolina since December. Federal health officials are urging vaccination as the U.S. recorded 2,280 cases in 2025.
U.S. Health Secretary Robert F. Kennedy Jr. claimed ketogenic diets can cure schizophrenia, but psychiatry experts say the assertion goes far beyond what current scientific evidence supports.
New research shows wearable devices can predict depression relapses weeks in advance through sleep pattern analysis, while studies reveal limitations in Apple Watch blood pressure alerts and benefits of replacing TV time with physical activity.
The FDA reversed its refusal to review Moderna's mRNA flu vaccine application after the company amended its submission. The agency will now consider full approval for adults 50-64 and accelerated approval for those 65 and older, with a decision expected by August 5, 2026.
The Trump administration launched TrumpRx.gov in February 2026, offering discounted prices on dozens of brand-name prescription drugs through negotiated deals with pharmaceutical companies, though critics warn many listed drugs have cheaper generic alternatives.
Hims and Hers Health pulled its $49 compounded version of Novo Nordisk's Wegovy weight-loss pill after the FDA referred the company to the Department of Justice for potential legal violations.
Analysts project AI in clinical trials will represent an $8 billion business segment by 2030, generating up to $110 billion per year in value to pharma. Multiple companies unveiled AI-powered platforms at SCOPE 2026 in Orlando.
The FDA placed clinical holds on Regenxbio's RGX-111 and RGX-121 gene therapies following a tumor case in an MPS I patient. The company's stock fell nearly 18% on the news.
The FDA has approved Filkri (filgrastim-laha), a biosimilar to Neupogen, for cancer patients at risk of infection due to chemotherapy and other indications. The approval marks Accord BioPharma's sixth biosimilar product.
